Developing a test to measure Alzheimer’s disease markers in cerebrospinal fluid
Multiplexed immunoassay for building patient-specific molecular profiles of CSF amyloid beta and TAU
['FUNDING_SBIR_2'] · ADEPTRIX CORPORATION · NIH-10707200
This study is working on a new test that looks at the fluid around your brain and spine to find certain proteins linked to Alzheimer's disease, which could help doctors diagnose it better and personalize treatments just for you.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ADEPTRIX CORPORATION (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10707200 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a specialized test that can analyze cerebrospinal fluid (CSF) to identify specific protein markers associated with Alzheimer's disease, namely amyloid beta and TAU. By using advanced techniques to capture and measure these proteins, the study aims to build detailed molecular profiles for individual patients. This could help in diagnosing Alzheimer's disease more accurately and tailoring treatments based on a patient's unique biomarker profile. The approach utilizes innovative technology to enhance the detection of these proteins, which are crucial for understanding the disease's progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with other types of dementia not related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostics and personalized treatment strategies for patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in using similar biomarker profiling approaches for Alzheimer's disease, indicating potential for success in this novel application.
Where this research is happening
BOSTON, UNITED STATES
- ADEPTRIX CORPORATION — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERGO, VLADISLAV — ADEPTRIX CORPORATION
- Study coordinator: BERGO, VLADISLAV
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease